Zobrazeno 1 - 8
of 8
pro vyhledávání: '"35"'
Autor:
Tord Hompland, Heidi Lyng, Bjørn Brennhovd, Therese Seierstad, A. Kathrine Lie, Harald Bull Ragnum, Sebastian Patzke, Knut Håkon Hole, Eva Katrine Aarnes, Ljiljana Vlatkovic
Publikováno v:
Cancer Research. 78:4774-4785
The established role of hypoxia-induced signaling in prostate cancer growth, metastasis, and response to treatment suggests that a method to image hypoxia in tumors could aid treatment decisions. Here, we present consumption and supply-based hypoxia
Autor:
Manuel Philco, Carlos Barrios, Heather Hinton, Igor Bondarenko, Shigehira Saji, Nicholas C. Turner, Ruffo Freitas-Junior, Qinshu Lian, Matthew Wongchenko, Denise Bradley, Rebecca Dent, Aruna Mani, Joyce O'Shaughnessy, Steven J. Isakoff, Sung-Bae Kim, Mafalda Oliveira
Publikováno v:
Cancer Research. 81:GS3-04
Background: In the randomized phase II LOTUS trial [Kim, Lancet Oncol 2017], adding IPAT to PAC improved progression-free survival (PFS), with a more pronounced effect in patients with PIK3CA/AKT1/PTEN-altered tumors. This effect provided the rationa
Autor:
M May, Annie Moisan, Florence Joly, F Marmé, Georgina Meneses-Lorente, J. Cortés, C Schindler, Andrés Cervantes, Jose A. Lopez-Martin, Maria Martinez-Garcia, Francesca Michielin, Iria Gonzalez, Anja Welt, TW Park-Simon, Joan Albanell, Ulrik Lassen, Maurizio Ceppi, Max Hasmann, Andreas Schneeweiss, Martin Weisser, Ian James, Celine Adessi, Wolfgang Jacob, Juan Miguel Cejalvo, Véronique Diéras
Publikováno v:
Cancer Research. 77:P6-11
Background: Inhibition of HER2 and HER3 heterodimerisation is a novel treatment concept in HER2-”low” expressing breast cancer (BC). Lumretuzumab, a glycoengineered monoclonal anti-HER3 antibody, in combination with pertuzumab has demonstrated sy
Autor:
Jung Ho Sohn, Wichit Arpornwirat, O Ocak Arikan, Y-C Chang, Roberta Valenti, Patricia Bastick, S-A Im, Hong-Ling Xue, KS Lee, Kadri Altundag, Alper Sevinc, TH Le, Hikmat Abdel-Razeq, Aycin Canatar, Y-H Im, Jae Ho Jeong, Ruchan Uslu, Rajnish Nagarkar, H-S Park, S-B Kim
Publikováno v:
Cancer Research. 76:P4-13
Background BOLERO-2 phase III trial established the efficacy of everolimus (EVE) plus exemestane (EXE) for the treatment of postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer (aBC). However, in this stu
Autor:
Samuel Aparicio, Anna V. Tinker, Philippe L. Bedard, Aaron R. Hansen, David W. Cescon, John Soong, Lesley Seymour, Hongbo Lui, Kathleen I. Pritchard, Dongsheng Tu, Linda Hagerman, John Hilton, Derek J. Jonker, Scott A. Laurie, Karen A. Gelmon, Rachel Anne Goodwin
Publikováno v:
Cancer Research. 80:PD4-02
Background: G-quadruplexes are secondary DNA structures that reversibly form in guanine-rich regions within DNA. Our group has demonstrated that CX-5461 selectively binds and stabilizes G-quadruplex structures, causing replication fork collapse and d
Autor:
Joseph J. Weber, Heidi R Umphrey, Julia White, Cindy B. Matsen, Emilia J Diego, Jennifer F. De Los Santos, Jamie L. Wagner, Peter C. Lucas, Thomas B. Julian, Christa R. Balanoff, Alastair M. Thompson, Reena S. Cecchini, Judy A. Tjoe, David Edmonson, Ursa Brown-Glaberman, Norman Wolmark, Mediget Teshome, Samantha A. Seaward, Irene Wapnir, Mark Basik, Eleftherios P. Mamounas, Antoinette R. Tan
Publikováno v:
Cancer Research. 80:GS5-05
Background: Increasing use of NCT regimens and improved selection of appropriate candidates has increased rates of pCR and has raised the question of whether surgical removal of the primary tumor is required for these patients (pts). To avoid surgery
Autor:
Atsushi Fujii, Takaaki Masuda, Masafumi Nakamura, Sho Nambara, Takao Otsuka, Yosuke Kuroda, Hidetoshi Eguchi, Shuhei Ito, Koshi Mimori
Publikováno v:
Cancer Research. 78:5395-5395
Background: Gastric cancer is one of the most common forms of cancer worldwide. The progression of chronic atrophic gastritis (CAG) is involved in gastric carcinogenesis. With the progression of chronic atrophic gastritis, the risk of gastric cancer
Autor:
Janet Elizabeth Pease, Geoffrey L. Uy, Hagop M. Kantarjian, Robert Godin, Jorge E. Cortes, Karen Keating, Kristen McEachern, Daniel J. DeAngelo, Mark D. Minden, Johann S. de Bono, Kenji Tamura, David Lorente, Karthick Vishwanathan, Emma Dean
Publikováno v:
Cancer Research. 76:CT147-CT147
AZD1208 is a potent oral ATP-competitive, pan-PIM kinase inhibitor. Here we report the results of 2 Phase 1, open-label, multi-center dose escalation studies, recruiting patients with recurrent or refractory AML or advanced solid tumors including mal